Quick Answer
BioNexus Gene Lab Corp reported Net Income of -$1.60 million for fiscal year 2024.
BioNexus Gene Lab Corp Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2024 | -$1.60M | +39.2% |
| 2023 | -$2.63M | -638.6% |
| 2022 | -$356.0K | -147.4% |
| 2021 | $751.6K | -31.3% |
| 2020 | $1.09M | +543.9% |
| 2019 | -$246.5K | -1031.7% |
| 2018 | $26.5K | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$709.0K | +47.3% | -15.1% |
| June 30, 2025 | -$616.2K | -409.5% | +1.1% |
| March 31, 2025 | -$623.3K | -500.8% | +53.7% |
| September 30, 2024 | -$1.35M | +48.4% | -775.7% |
| June 30, 2024 | $199.1K | +176.8% | +291.9% |
| March 31, 2024 | -$103.8K | -50.2% | +96.0% |
| September 30, 2023 | -$2.61M | -3271.0% | -906.4% |
| June 30, 2023 | -$259.3K | -87.0% | -275.4% |
- BioNexus Gene Lab Corp showed an increase of +39.2% in Net Income compared to the prior fiscal year.
- Over the 2018–2024 period, BioNexus Gene Lab Corp’s net income has declined by 6142.0% (from $26.5 thousand to -$1.60 million).
- The most recent figure is from BioNexus Gene Lab Corp’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: